According to Gartner, by 2028, "33% of enterprise software applications will incorporate agentic AI, a significant rise from ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

Juan Loaiza had a startling wake-up call: companies that fail to recognize the new role of databases may soon find themselves digital dinosaurs in an era where data architecture determines destiny.

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

Data Exfiltration Capabilities: Well-crafted malicious rules can direct AI tools to add code that leaks sensitive information while appearing legitimate, including environment variables, database ...

In this piece, Tass Kalfoglou, the director of our APAC Business Unit, sheds light on supply chain vulnerabilities and the ...

As global organisations gear up for an AI-powered future, businesses need databases that can handle massive workloads and ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1bn, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, and ...

GenAI adds new risks to the software development process, including vulnerabilities, copyright restrictions, and data ...

ESET researchers uncovered MirrorFace activity that expanded beyond its usual focus on Japan and targeted a Central European ...